Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study

A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.